Last reviewed · How we verify
NCT06209866
The Role of Glass Stage Compared to WIFI Stage in Predicting Limb Salvage
trial testing PTA in Chronic Limb-Threatening Ischemia in 28 participants. Status unknown.
1 January 2026
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 28 |
| Start date | 1 February 2024 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 February 2026 |
Drugs / interventions tested
- PTA
Conditions studied
- Chronic Limb-Threatening Ischemia — all drugs for Chronic Limb-Threatening Ischemia →
Sponsor
Assiut University
Who can join
Eligibility, any sex, with Chronic Limb-Threatening Ischemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
compare between GLASS and WIFI Staging in predicting limb salvage in patients with chronic limb threatening ischemia ( CLTI) undergoing endovascular revascularization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06209866
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PTA
Trials testing the same drug.
- NCT05345431 — Endovascular Denervation for the Treatment of Patients With Peripheral Arterial Disease · NA · recruiting
- NCT04123639 — Outcomes of Endovascular Treatment of Superficial Femoral Artery In-stent Restenosis · NA · unknown
- NCT04060797 — Endovascular Denervation Improves Limb Ischemia in Patients With Peripheral Artery Disease · NA · completed
- NCT02963649 — IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA · NA · completed
Other recruiting trials for Chronic Limb-Threatening Ischemia
Currently open trials in the same condition.
- NCT07352800 — Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-thr · Phase 2 · recruiting
- NCT06879561 — Pressure Wire Guidance for Infrapopliteal Artery Interventions · NA · recruiting
- NCT06071429 — Bioresorbable Sirolimus-Eluting Scaffold Treatment for Below the Knee Disease · NA · recruiting
- NCT06656364 — Esprit BTK Post-Approval Study · NA · active not recruiting
- NCT07330635 — Chronic Wounds and Blood Circulation Detection · NA · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06209866 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 23 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06209866.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing